Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients
Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is requi...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-10-01
|
| Series: | Diagnostics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-4418/10/11/864 |
| _version_ | 1797550031363899392 |
|---|---|
| author | Csilla Olah Stephan Tschirdewahn Michèle J. Hoffmann Ulrich Krafft Boris Hadaschik Peter Nyirady Attila Szendröi Orsolya Módos Anita Csizmarik Ilona Kovalszky Henning Reis Tibor Szarvas |
| author_facet | Csilla Olah Stephan Tschirdewahn Michèle J. Hoffmann Ulrich Krafft Boris Hadaschik Peter Nyirady Attila Szendröi Orsolya Módos Anita Csizmarik Ilona Kovalszky Henning Reis Tibor Szarvas |
| author_sort | Csilla Olah |
| collection | DOAJ |
| description | Cisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (<i>p</i> = 0.009) and female patients (<i>p</i> = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, <i>p</i> = 0.048; HR: 2.269, 95%CI: 1.053–4.887, <i>p</i> = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making. |
| first_indexed | 2024-03-10T15:23:42Z |
| format | Article |
| id | doaj.art-71490fd378244d5eb3504b56efadd800 |
| institution | Directory Open Access Journal |
| issn | 2075-4418 |
| language | English |
| last_indexed | 2024-03-10T15:23:42Z |
| publishDate | 2020-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Diagnostics |
| spelling | doaj.art-71490fd378244d5eb3504b56efadd8002023-11-20T18:16:40ZengMDPI AGDiagnostics2075-44182020-10-01101186410.3390/diagnostics10110864Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer PatientsCsilla Olah0Stephan Tschirdewahn1Michèle J. Hoffmann2Ulrich Krafft3Boris Hadaschik4Peter Nyirady5Attila Szendröi6Orsolya Módos7Anita Csizmarik8Ilona Kovalszky9Henning Reis10Tibor Szarvas11Department of Urology, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Urology, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Urology, Medical Faculty, Heinrich-Heine-University Duesseldorf, 40225 Duesseldorf, GermanyDepartment of Urology, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Urology, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Urology, Semmelweis University, 1089 Budapest, HungaryDepartment of Urology, Semmelweis University, 1089 Budapest, HungaryDepartment of Urology, Semmelweis University, 1089 Budapest, HungaryDepartment of Urology, Semmelweis University, 1089 Budapest, Hungary1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, 1085 Budapest, HungaryInstitute of Pathology, University of Duisburg-Essen, 45147 Essen, GermanyDepartment of Urology, University of Duisburg-Essen, 45147 Essen, GermanyCisplatin-containing chemotherapy represents the first-line treatment for patients with locally advanced or metastatic muscle-invasive bladder cancer. Recently, novel therapies have become available for cisplatin-ineligible or -resistant patients. Therefore, prediction of cisplatin response is required to optimize therapy decisions. Syndecan-1 (SDC1) tissue expression and serum concentration may be associated with cisplatin resistance. Thus, pre-treatment serum levels of SDC1 and its expression in chemo-naïve tissues were assessed in 121 muscle-invasive bladder cancer patients who underwent postoperative platinum-based chemotherapy. SDC1 concentrations were evaluated by ELISA in 52 baseline and 90 follow-up serum samples and tissue expressions were analyzed by immunohistochemistry in an independent cohort of 69 formalin-fixed paraffin-embedded tumor samples. Pre-treatment SDC1 serum levels were significantly higher in lymph node metastatic (<i>p</i> = 0.009) and female patients (<i>p</i> = 0.026). SDC1 tissue expression did not correlate with clinicopathological parameters. High pre-treatment SDC1 serum level and the presence of distant metastasis were independent risk factors for overall survival (Hazard ratio (HR): 1.439, 95% Confidence interval (CI): 1.003–2.065, <i>p</i> = 0.048; HR: 2.269, 95%CI: 1.053–4.887, <i>p</i> = 0.036). Our results demonstrate an independent association between high baseline serum SDC1 concentration and poor survival in platinum-treated patients. Analyzing baseline serum SDC1 levels may help to predict platinum-containing chemotherapy and could help to optimize therapeutic decision-making.https://www.mdpi.com/2075-4418/10/11/864muscle-invasive bladder cancerSDC1chemotherapycisplatinmetastasisMatrix Metalloproteinase—7 (MMP-7) |
| spellingShingle | Csilla Olah Stephan Tschirdewahn Michèle J. Hoffmann Ulrich Krafft Boris Hadaschik Peter Nyirady Attila Szendröi Orsolya Módos Anita Csizmarik Ilona Kovalszky Henning Reis Tibor Szarvas Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients Diagnostics muscle-invasive bladder cancer SDC1 chemotherapy cisplatin metastasis Matrix Metalloproteinase—7 (MMP-7) |
| title | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
| title_full | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
| title_fullStr | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
| title_full_unstemmed | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
| title_short | Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients |
| title_sort | soluble syndecan 1 levels are associated with survival in platinum treated bladder cancer patients |
| topic | muscle-invasive bladder cancer SDC1 chemotherapy cisplatin metastasis Matrix Metalloproteinase—7 (MMP-7) |
| url | https://www.mdpi.com/2075-4418/10/11/864 |
| work_keys_str_mv | AT csillaolah solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT stephantschirdewahn solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT michelejhoffmann solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT ulrichkrafft solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT borishadaschik solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT peternyirady solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT attilaszendroi solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT orsolyamodos solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT anitacsizmarik solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT ilonakovalszky solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT henningreis solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients AT tiborszarvas solublesyndecan1levelsareassociatedwithsurvivalinplatinumtreatedbladdercancerpatients |